Completed
PHASE2
INTERVENTIONAL
NCT04881760
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
Interventions
Name:
LY3437943
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Mean Percent Change From Baseline in Body Weight
TimeFrame:
Baseline, Week 24
Description:
Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Baseline BMI (\< 36kg/m2 vs. \>=36 kg/m2)\*Time + Sex (Female vs. Male)\*Time + Baseline\*Time.
Trial Information
NCT ID
NCT04881760
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025